Glyxambi Is the First SGLT2/DPP-4 Inhibitor Oral Combo for Type 2 Diabetes

April 2017

You'll see Glyxambi (glik-SAM-bee), a new combo for type 2 diabetes.

It contains the SGLT2 inhibitor empagliflozin (Jardiance)...with the DPP-4 inhibitor linagliptin (Trajenta).

Glyxambi will be promoted for patients who aren't at their glycemic goal with metformin plus either linagliptin or empagliflozin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Geriatrics Take Steps to Help Seniors Prevent Falls
Asthma Don't Be Surprised if Some Adults Step Down Asthma Meds
Gastroenterology Help Parents With Concerns About Restoralax and Neuropsych Effects in Children
Diabetes Glyxambi Is the First SGLT2/DPP-4 Inhibitor Oral Combo for Type 2 Diabetes
Hepatitis C Put Warnings About Liver Damage With Hep C Meds Into Perspective
Neurology & Pain Explain When Iron Supplements Might Help Restless Legs Syndrome
Women's Health Help Identify Women at Risk of Postpartum Depression
Topicals Point Out Pros and Cons of Different Topical Dosage Forms
Heart Failure Think of Lancora as a Niche Drug for Heart Failure
Heart Failure Focus on BP Control for "Diastolic" or Preserved Ejection Fraction Heart Failure
Neuromuscular Recommend Baclofen or Gabapentin for Persistent Hiccups